Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Prof Finkelstein current and only A-rated researcher in Probability and Statistics in SA
2014-10-28



Prof Maxim Finkelstein
Photo: Johan Roux
Prof Maxim Finkelstein from the Department of Mathematical Statistics at the University of the Free State (UFS) received an A-rating from the National Research Foundation (NRF). This makes him the only A-rated researcher in ‘Probability and Statistics’ regarding Mathematical Sciences in the country.

According to the NRF-rating process, a person with an A-rating is a world leader in his field. 

Prof Jonathan Jansen, Vice-Chancellor and Rector, said: "I am absolutely delighted for Professor Finkelstein and for the fact that this is one of the clearest signs that the UFS has significantly increased its standards of research across the institution as a whole."

Prof Finkelstein says this rating means a great deal to him, since it is a reflection of his dedication and perseverance.

“Of course, the rating is not a goal in itself,” Prof Finkelstein says. “The goal is the high quality research and the rating is just an objective indication of this. Along with the satisfaction, this rating brings the responsibility for maintaining this high status in the future.”

Prof Finkelstein conducts his general research in the field of ‘Probability and Statistics’, but his specific area of focus is ‘Stochastic Modelling’. Prof Finkelstein solely lectures postgraduate students and also mentors a few master’s and PhD students. This affords him the time to mainly concentrate on his research.

“Finally, I wish to emphasise the fact that high-quality research became the prime goal at the UFS,” says Prof Finkelstein. He underscores the efforts of the Vice-Chancellor and the Vice-Rector: Research in creating excellent possibilities for researchers. This has already resulted in remarkable improvements in the UFS’s research outputs – and consequently an increase in the number of rated researchers at the university.

A total of 119 UFS researchers currently have evaluation and rating status from the NRF, says Nico Benson, Deputy Director: Research Development. Currently (October 2014) 29 researchers are still waiting for response from the NRF regarding applications submitted. A total of 16 ratings are already known. On the Qwaqwa Campus of the UFS, five researchers are rated.

Prof Finkelstein's A-rating will become effective from 1 January 2015. Ratings are valid for a period of six years and researchers are invited to apply for re-evaluation in the fifth year.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept